The Synthesis and Biological Properties of ... - ACS Publications

(C11HlsO$1) C, H. l-Chloro-2,5-d~-~-acety~-cr-~-g~ucofururono~actone. (XXXII).-. 1,2,3-Tr~-0-acety~-a-D-g~ucofururono~actone30c (XXXI) (83 g,. 0.28 mo...
0 downloads 0 Views 355KB Size
m y igm

HPDROXYLAhlINOPURIn'ES

bath for 2 hr with protection from atmospheric moisture. The NaCl was removed by filtration and HzO was added to the filtrate until turbitidity appeared. An amber oil formed within 20 min, which, on scratching, crystallized. The crystals were washed (H20) and recrystallized from 50% EtOH; mp 87-89', yield 11.4 g (83%). Anal. (C28H38018S.H20) C, H. 2,3,4-Tri-0-acetyl-a-~-ribopyranosyl Chloride (XXIX).1,2,3,4-Tetra~-acetyl-a-~-ribopyranose~~ waa converted to X X I X by an adaptation of the PacsugO procedure, yield Slcl,, mp 93-95", lit.31mp 9 5 O . Anal. (C11HlsO$1) C, H. l-Chloro-2,5-d~-~-acety~-cr-~-g~ucofururono~actone (XXXII).1,2,3-Tr~-0-acety~-a-D-g~ucofururono~actone30c (XXXI) (83 g, 0.28 mole) was dissolved in 500 ml of CHCh (U.S.P.) and 44 g (0.23 mole) of Ticla was added slowly with stirring. After stirring for 3.5 hr a t 2j0, the solution was poured into 2 1. of ice water. The CHCL layer was washed (5% NaHC03, H,O), dried (Na2S04), decolorized with charcoal, and concentrated to a syrup in vacuo a t 50". The syrup was dissolved in anhydrous ether and a fine white crystalline product precipitated, yield 20 g (26%), mp 152-157", [cY]~'D+240° ( c 2.0,CHC13). Anal. (CioHiiO7Cl) C, H. Goebel and Babers30bprepared X X X I I by a different method D (c 1.257, CHC13). and reported mp 107.5-108.5" and [ O ~ ] ~ O95.5' (31) H . Zinner, Chem. Ber., 83, 153 (1950).

52 1

It is possible that this large discrepancy in melting point and optical rotation represents two stereoisomers, although the optical rotation of XXXII reported here is close to that of the analogous l-bromo-2,4-d~-~-acety~-cr-~-g~ucofuriirono~actone, [ a I z 5 D +236", mp 138-130'. Hydrolysis of 6-Purinyl thio glycoside^.^^ (a) Acid Catalysis solutions were prepared to contain 0.23 (Figure 1).-Stock pmole of thioglycosides/ml in H20. One milliliter of stock solution was diluted to 10.0 ml with appropriate buffers. Periodic readings of uv absorption were recorded a t 280 mp and 325 mp. Decreased absorbance a t 280 mp with simultaneous increase a t 323 mp demonstrated hydrolysis of the thioglycoside with liberation of 6 3 1 P in solutions with pH values below 5. Products of hydrolysis were further identified by paper chromatography. The thioglycosides here described were stable a t neutral and alkaline pH values, but were readily hydrolyzed in dilute acid. ( b ) Enzyme Catalysis.-Hydrolysis of purine thioglycosides is catalyzed by a wide variety of mammalian thioglycosidase.2a The action of hog liver thioglycosidase on 11PG is illustrated in Figure 2. (32) Details concerning t h e kinetics of hydrolysis, t h e preparation, and t h e properties of mammaliad and other thioglycosidases will appear in a subsequent publication.

The Synthesis and Biological Properties of Hydroxylaminopurines and Related Derivatives1 A. GINER-SOROLLA, S. A. O'BRYANT, C. SANOS, 11. R. DOLLINGER, A. BENDICH, .4SD J. H. BURCHEXAL Divisions of Biological Chemistry and Drug Resistance, Sloan-Kettering Institute for Cancrr Research, and Sloan-Kettering Division, Graduate School of ilfpdical Sciences, Cornell Universzty Medical College, &Yew York, LYew York 10021 Received December 91, 1967 Syntheses are described for the preparation of substituted hydroxylaminopurines, the related methoxyamino, methylhydroxylamino, methylhydrazino, and methylmercapto derivatives, and some ribonucleosides thereof. These compounds were tested against L1210 mouse leukemia. Two compounds, 6-methoxyaminopuririe and 2-hydroxylamino-6-methylmercaptopurine, were active against the parent L1210 line but not against a subline resistant to 6-mercaptopurine, suggesting that they may be converted to active nucleotides by a mechanism similar to that of 6-mercaptopurine.

The marked inhibition of several mouse leukemias its 2by &hydroxylamino-9-/3-D-ribofuranosylpurine,* amino derivative,a and 2,6-dihydroxylaminopurine and its ribosyl derivative4 indicates that hydroxylamino derivatives of purines or their nucleosides are worthy of further investigation as potential chemotherapeutic agents. We now report the synthesis and biological activity of other substituted hydroxylaminopurines as well as related methoxyamino, methylhydroxylamino, and methylhydrazino derivatives and their nucleosides. Reaction of 8-methylthi~purine~ (I) with ethanolic (1) This investigation was supported b y funds from t h e National Cancer Institute (Grant No. CA 08748), T h e Atomic Energy Commission (Contract No. AT[30-1?,910), a n d aided by G r a n t No. T-128F from t h e American Cancer Society, Grant T45, a n Ethel A. Shaffer Memorial Grant for Cancer Research from t h e American Cancer Society, and U. S. Public Health Service Fellowship No. 1-F3-CA-32,812 (M. R. D.). (2) (a) A. Giner-Sorolla, L. Medrek, and A. Bendich, 150th National Meeting of t h e American Chemical Society, Atlantic City, N. J.. Sept 1965, p 5P; (b) A. Giner-Sorolla, Calenica Acta, 19, 97 (1966); (0) 4. GinerSorolla, L. Medrek, and A. Bendich, J . M e d . Chem., 9, 143 (1966); (d) J. H. Burchenal, J. J. Fox, A. Giner-Sorolla, and A. Bendich, X I t h Congress of t h e International Society of Hematology, Sydney, Australia, 1966, p 227; (e) J. H. Burchenal, M. Dollinger, J. Butterbaugh, D. Stoll, and A. GinerSorolla, Biochem. Pharmacol., 16, 423 (1967). (3) A. Ginw-Sorolla, S. A. O'Bryant, J. H. Burchenal, and A. Bendich, Biochemistry, 6 , 3057 (1966). (4) (a) A. Giner-Sorolla, C . Nanos, M. R. Dollinger. J. H . Burchenal, and A. Bendich, J . M e d . Chem., 11, 52 (1968); (b) hI. R. Dollinger, J. H. Burchenal, and A. Giner-Sorolla, in preparation. ( 5 ) D. J. Brown and S. F. Xason, J . Chem. Soc., 682 (1957).

hydroxylamine in the presence of a catalytic amount of chloride ions3 led to S-hydroxylaminopurine (11) (Table I). When 2-fluoro-6-mercaptopurine6 (111) was treated with the hydroxylamine solution, substitution of the 2-fluor0 was accompanied by hydrolysis of the mercapto group, leading to the known7 2-hydroxylamino - 6- hydroxypurine (IV) . When 2 -fluor0 - 6 methylthiopurine (V) was similarly treated, 2-hydroxylamino-6-methylthiopurine (VI) was obtained, even in the presence of a catalytic amount of chloride ions. This behavior contrasts with the ease of replacement of a 6-thiomethyl group by hydroxylamino when the Cfis substituted by SH,.3 Upon reaction with hydroxylamine in the presence of chloride ions, 2,6-dichloropurine* (VII) afforded 2chloro-6-hydroxylaminopurine (VIII). This is analogous to the reported conversion of VI1 to 2-chloro6-aminopurine upon aminolysis. (6) J. A. Montgomery and K. Hewson, J . A m . Chem. Soc.. 8 2 , 463 (1960). (7) 2-Hydroxylarnino-6-hydroxypurine has been described recently by J. F. Gerster and R. K. Robins [ J . O w . Chem., 31, 3258 (1966)) who prepared it from 2-fluoro-6-hydroxypurine. (8) (a) J. A. Montgom'ery, J . A m . Chem. Soc.. '78, 1928 (1956); (b) G. B. Elion and G. H. Hitchings, {bid., 7 8 , 3508 (1956): (0) A. G. Beaman and R. K. Robins. J . A p p l . Chem., 12, 432 (1962). (9) (a) J. A. Montgomery and L. Holum, J . A m . Chem. Soc., '79, 2185 (1957); (b) G. B. Brown a n d V. S. Weliky, J . Orp. Chem., 23, 125 (1958); (0) S. R. Breshears, S. S. Wang. 8. G. Bechtholt, and D. E . Christensen, J . A m . Chem. Soc., 81, 3789 (1959).

II i

-

- i

Experimental Section The data relating t o the synthesis of these compounds are listed iri Table I and the iiv spectra of some of the new derivatives are giver1 in Table 11. The remainder exhibit expected A,,,.,, values ibetweeii 260-270 nip) at pH 6.8. Treatment with Raney Nickel of the Hydroxylamino Derivatives.--The hydroxylamino derivative ( 2 5 mg) was dissolved iii ..

( I O ) F. S. Philips. personal cominunicatiun. (11) XI. Rockmell and XI. 11. Mapuire, .Val. Pharmacol., 2, 5 i - I (1966). ( 1 1 ) (a) G . \V. Caniiener and C. G. Smith, Biochem. Pharmacol., 14, 1-10.? (19fi5); (11) C. G. Smith. H. H. Ruskirk, and \V. C . Lummis, Pror. A m . .4ssoc. Cancer Res., 6 , 60 (19fi.5): (c) hl. R. Dollinger, J. H. Burchenal, iV.

Icreis, and J. J . Fox., Biochem. Pharmacol., 16, 689 (1967). (13) € I . J. Schaeffer a n d P.8. Bhargava, Biochemistry, 4, 71 (1965). (1-1) (a) \Y. I3ollag and 1'. Grunherg. Ezperientia, 19, 130 (1963); (b) lessandri, [I. ,J. Keel. a n d I\-. Bollag, Cancer Chemotherapv ; ( e ) \ \ . lireis and \V. T e n , Ezperientia, 21, 284 (1965). ( 1 5 ) UT spectra \vert: determined with a Cary recording spectrophotomet e r , Alodei 11. .\icending paper chromatography was run on Whatman No. 1 paper i n t h e follon-ing solvent systems: concentrated NH4OH-H?O-iI'rOH (10: P O : 70). r i - H u C ) I I-- H?O-.\eOH ( 5 0 :2 5 : 2 5 ) , and 1 .\f KH4O.\c-. Et011 (35:iO). The. ilrterinination of melting points was carried uut \\.it11 it 3Iel-Trinp ineltine I m i i i t auparatus and t h e temperatures were corrertecl. .\nalysea were perfurnid 1,)- Spang Microanalytical Lahoratory, . \ n n .irbor, Xich. TT'here analyses are indicated by t h e symbols of t h e elements only, analytical results obtained for these elements were within k0.370 of the calculated values.

523

l l a y 1RRS TABLE I1 UV 7-p

Compd

0.1 .V HC1

I1

208 (33.70) 295 (32.56)

208 (41.65) 265 (15.94) 350 (26.96) 210 (24.70) VI 244 (17.60) 278 (24.56) 317 (21.30) 0.1 31 sodium phosphate solution.

IT‘

Q

SPK:CTR.ILPROPERTIES Amsxl mp (c X

OF

SOME

IIYUROIUl’I,.~.\lINO~lU~INKS Amin, mp ( e X

10-9

p H 7a

204 (24.15) 241 (3.40) 285 (14.90) 210 (17.73) 265 (7.40) 342 (17.34) 218 (15,30) 246 (12.65) 293 (17.17)

I -

10-9

0.1 .V N a O H

0.1 N HCI

pH 7 a

0.1 .V NaOH

324 (7.32)

249 (2.84)

251 (3.32)

253 (2.16)

216 (12.40) 313 (13.61)

243 (9.64) 304 (3.87)

247(6.17) 297 (1.84)

268 (6.50)

269 (17.71) 294 (17.45) 352 (4.50)

228 (20.95) 237 (17.18) 258 ( 1 3 . 7 3 296 (15.72)

231 (8.54) 275 (4.47)

260 (14.92) 321 (4.20)

aqueous 57, NHaOH (10 ml), Raney nickel (100 mg) was added, and the mixture refluxed for 1-3 hr. The corresponding amino derivatives were identified by IIV spectra ( a t pH 1, 7, and 11) and paper chromatography. I n the case of 2-hydroxylamino-6niethylthiopurine (VI), a simultaneous desulfuration to 2-aminopurine occurred and 2-chloro-6-hydroxylaminopurine (VIII) waa converted into adenine. Biological Activity.-Purine derivatives were evaluated by methods previously describedlz0for their activity against L1210 mouse leukemia (Table 111). Compounds were administered intraperitoneally to groups of ten mice daily for ten doses beginning l day after intraperitoneal injection of leukemic cells. Results (Table 111) are expressed as increased life span (ILS, %) of treated animals as compared to controls. Compounds active against the parent L1210 line of leukemia were tested against a subline resistant to 6-mercaptopurine (L1210/6-3IP). Two compounds, 6-methoxyaminopurine ( X I I ) and 2-hydroxylamino-6-methylthiopurine (VI), were active against L1210 but not L1210/6-3\lP. The antitumor activity of 6 - N P has been ascribed to its conversion to an active nucleotide by IMP-GXP pyrophosphorylase. Since the L1210/6-3IP line is deficient in this enzyme activity,lG it is likely that these two purines are similarly transformed into active nucleotides by a mechanism analogous to that of 6-3IP. 8-Hydroxylaminopurine (11)and 9-p-~-ribofuranosyl-6-methylhydroxylaminopurine (XVI) were tested against the Ridgway osteogenic sarcoma. Comparison of tumor growth in treated as compared to control mice showed no significant tumor inhibition. 9-Hydroxyethyl-6-hydroxylaminopurine( X ) was evaluated as an inhibitor of adenosine deaminase, using the screening system proposed by Schaeff er and Odin.” Incubation of adenosine (0.066 m M ) in phosphate buffer at pH 7.6 a i t h adenosine deaminase (Sigma), in the presence of S in a concentration three times that of adenosine, resulted in a 20.2c7, inhibition of deamina(16) R. W.Brockman, L. L. Bennett, Jr., M. S. Simpson, A. R. Wilson, J. R. Thomson, and H . E. Skipper. Cancer Res., 19, 856 (1958). (17) H. J. Schaeffer and E. Odin, J . M e d . Chem., 9, 576 (1966).

TABLE I11 ACTIVITY OF PURINE DERIVATIVES GAIN ST L1210 ~ I O V L SEEC K E Y I ~

Compd

Leuksmia

Dose, w/kga daily x 10

Survival, days (treated/ control)

ILS,

%*

I1 VI11 XI1

L1210 50 9.018.0 +12 L1210 23 8 . 7 i 8 . 6 +1 L1210 100 13.8/7.7 +79 L1210/6-MPC 100 8 . 1 / 9 . 3 -13 L1210 400 XIV 8.6/8.1 +6 L1210 100 XV 9.3/8.1 +I5 L1210 XVI 200 8.0/8.1 -1 L1210 30 XVII 9.3/9.5 -2 L1210 XVIII 50 8.9/9.5 -6 L1210 30 XX 9.2/9.5 -3 L1210 1’1 12.5 14.018.6 +63 L1210/6-31Pc 25 8.719.2 -5 L1210 23 x 9.619.4 + 2 L1210 10 6-Mercaptopurine 15.9/9.5 +68 a Dose reported in highest dose tested that did not result in acute toxicity (weight loss). * Increased life span. Values less than 25 are considered not significant; values from 25 to 50 are considered moderately significant; values greater than 50 are considered highly significant. Resistant to 6-mercaptopurine. tion of adenosine, measured as loss in optical density a t 265 mp between 1 and 6 min after addition of enzyme. This inhibition of adenosine deaminase is considered as not significant.

Acknowledgment.-The authors wish t o thank Dr. George B. Brown for valuable discussion and t o Dr. G. Tarnowski for the screening data on Ridgway osteogenic sarcoma.